Truvada Adverse Reactions

Clinical Trials: TRUVADA: Four hundred and forty-seven HIV-1 infected patients have received combination therapy with EMTRIVA and VIREAD with either a non-nucleoside reverse transcriptase inhibitor or protease inhibitor for 48 weeks in clinical studies.
Study 934 - Treatment Emergent Adverse Events: Adverse events observed in this study were generally consistent with those seen in other studies in treatment experienced or treatment-naïve patients receiving VIREAD and/or EMTRIVA (see Table 9).

Click on icon to see table/diagram/image

Laboratory Abnormalities: Laboratory abnormalities observed in this study were generally consistent with those seen in other studies of VIREAD and/or EMTRIVA (see Table 10).

Click on icon to see table/diagram/image

In addition to the events described previously for study 934, other adverse events that occurred in at least 5% of patients receiving EMTRIVA or VIREAD with other antiretroviral agents in clinical trials include anxiety, arthralgia, increased cough, dyspepsia, fever, myalgia, pain, abdominal pain, back pain, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), pneumonia, rhinitis and rash event (including rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash and allergic reaction).
Skin discoloration has been reported with higher frequency among EMTRIVA-treated patients. Skin discoloration, manifested by hyperpigmentation on the palms and/or soles was generally mild and asymptomatic. The mechanism and clinical significance are unknown.
In addition to the laboratory abnormalities described previously for study 934, grade 3/4 elevations of bilirubin (>2.5 x ULN), pancreatic amylase (>2.0 x ULN), serum glucose (<40 or >250 mg/dL), serum lipase (>2.0 x ULN), and urine glucose (≥3+) occurred in up to 3% of patients treated with EMTRIVA or VIREAD with other antiretroviral agents in clinical trials.
For more information, please consult the EMTRIVA and VIREAD package inserts.
Post-Marketing Experience: EMTRIVA: No additional events have been identified for inclusion in this section.
VIREAD: The following events have been identified during post-approval use of VIREAD. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion because of a combination of their seriousness, frequency of reporting or potential causal connection to VIREAD.
Immune System Disorders: Allergic reactions.
Metabolism and Nutritional Disorders: Hypophosphatemia, lactic acidosis.
Respiratory, Thoracic, and Mediastinal Disorders: Dyspnea.
Gastrointestinal Disorders: Abdominal pain, increased amylase, pancreatitis.
Hepatobiliary Disorders: Increased liver enzymes, hepatitis.
Skin and Subcutaneous Tissue Disorders: Rash.
Musculoskeletal and Connective Tissue Disorders: Myopathy, osteomalacia (both associated with proximal renal tubulopathy).
Renal and Urinary Disorders: Renal insufficiency, renal failure, acute renal failure, Fanconi syndrome, proximal tubulopathy, proteinuria, increased creatinine, acute tubular necrosis, nephrogenic diabetes insipidus, polyuria, interstitial nephritis (including acute cases).
General Disorders and Administration Site Conditions: Asthenia.